PMGC Holdings ELAB
NASDAQ ELAB
$6.66 +0.56 (+9.18%)
At close: Aug 21, 2026 · 4:00 PM EDT

PMGC Holdings (ELAB) Consolidated Net Income (2022 - 2026)

PMGC Holdings (ELAB) posted Consolidated Net Income of $19501.0 for Q1 2026, down 10.29% sequentially from $21738.0 in Q4 2025, and up 170.54% YoY from $7208.1 in Q1 2025.

PMGC Holdings (ELAB) Consolidated Net Income (2022 - 2026) Analysis & Trends

PMGC Holdings has reported Consolidated Net Income for 5 years, with the latest figure at $19501.0 in Q1 2026.

  • Quarterly Consolidated Net Income rose 170.54% year-over-year to $19501.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80072.0 (up 105.71% YoY) and the FY2025 annual result came in at $32927.0, up 101.48% from the prior year.
  • Consolidated Net Income declined to $19501.0 in Q1 2026 per ELAB's latest filing, from $21738.0 in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $1.1 billion in Q4 2022 and troughed at -$469.3 million in Q3 2022.
  • A 5-year average of $24.6 million and a median of -$299404.0 in 2024 frame the typical range for Consolidated Net Income.
  • The sharpest annual moves came in 2024 and 2026: Consolidated Net Income tumbled 121.83% in 2024, then soared 170.54% in 2026.
  • Over 5 years, Consolidated Net Income stood at $1.1 billion in 2022, then sank by 100.1% to -$1.1 million in 2023, then jumped by 79.96% to -$216910.0 in 2024, then soared by 110.02% to $21738.0 in 2025, then retreated by 10.29% to $19501.0 in 2026.
  • According to Business Quant data, Consolidated Net Income over the past three periods registered $19501.0, $21738.0, and $21698.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 482.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -782.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 237.01 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 164.49 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -174.37 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -13.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 81.49 Mn
10 PMGC Holdings 31.22 Mn 12.43 Mn 385,691.00 -4.31 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 19,501.00
Dec 31, 2025 21,738.00
Sep 30, 2025 21,698.00
Jun 30, 2025 17,135.00
Mar 31, 2025 -27,644.00
Dec 31, 2024 -216,910.00
Sep 30, 2024 -299,404.00
Jun 30, 2024 -859,580.00
Mar 31, 2024 -1.87 Mn
Dec 31, 2023 -1.08 Mn
Sep 30, 2023 -270.32 Mn
Jun 30, 2023 -1.06 Mn
Mar 31, 2023 -843,918.00
Dec 31, 2022 1.11 Bn
Sep 30, 2022 -469.32 Mn